Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis

Kathleen F Walsh; Stalz Charles Vilbrun; Ariadne Souroutzidis; Joshua Ellis; Sobiesyke Delva; Guy Joissaint; Kathryn M Dupnik; Patrice Joseph; Jean W Pape; Serena P Koenig

doi:10.1093/ofid/ofac440

Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis

Open Forum Infect Dis. 2022 Aug 29;9(9):ofac440. doi: 10.1093/ofid/ofac440. eCollection 2022 Sep.

Authors

Kathleen F Walsh^{1

2}, Stalz Charles Vilbrun³, Ariadne Souroutzidis⁴, Joshua Ellis⁵, Sobiesyke Delva³, Guy Joissaint³, Kathryn M Dupnik^{1

6}, Patrice Joseph³, Jean W Pape^{1

3}, Serena P Koenig⁷

Affiliations

¹ Center for Global Health, Weill Cornell Medicine, New York, New York, USA.
² Division of General Internal Medicine, Weill Cornell Medicine, New York, New York, USA.
³ Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti.
⁴ The Analysis Group, Boston, Massachusetts, USA.
⁵ Harvard Medical School, Boston, Massachusetts, USA.
⁶ Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
⁷ Brigham and Women's Hospital, Boston, Massachusetts, USA.

Abstract

Patients with multidrug-resistant tuberculosis who received regimens containing high-dose isoniazid (INH^HD) had similar time to culture conversion and treatment outcomes as patients who received regimens with bedaquiline. INH^HD is an inexpensive and safe medication that may contribute additive efficacy in combination regimens.

Keywords: bedaquiline; drug-resistant tuberculosis; high-dose isoniazid; time to culture conversion; treatment outcomes.

Abstract

Grants and funding